India initiates anti-dumping probe on Pen-G, salts from China
India has launched an anti-dumping investigation into Penicillin G imports from China following a complaint by Lyfius Pharma. The company claims that cheap imports are hindering the domestic production of this critical antibiotic ingredient.
Why it matters
This move is part of India's broader strategy to reduce dependency on foreign pharmaceutical imports and bolster domestic manufacturing under the PLI scheme.
India has initiated an anti-dumping investigation into imports of Penicillin G and its salts from China after domestic manufacturer Lyfius Pharma alleged the imports were causing material retardation to the industry.
The company has sought imposition of anti-dumping duties, the Directorate General of Trade Remedies, under the Ministry of Commerce and Industry, said in a notification initiating the investigation.
The Aurobindo Pharma subsidiary began manufacturing Penicillin G more than two years ago under the government’s production linked (PLI) scheme and with it revived production of the beta-lactam antibiotic in the country after about three decades.
Stating that it is the sole eligible producer of the product under consideration (PUC) in India and there are no other domestic manufacturers, Lyfius Pharma, in the application, said India used to previously manufacture Penicillin G before sustained influx of imports ceased domestic production.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in